Dr David Brookes has experience in the health and biotechnology industries. He first became involved in the biotechnology sector in the late 1990s as an analyst, and continues to be a clinician and as a biotechnology industry consultant.
Dr Brookes has since held board positions in numerous ASX-listed biotechnology companies including as chair of genomics solutions company RHS, which was acquired by PerkinElmer Inc (NYSE:PKI $9B biotech company) in June 2018. He has also been a chair and member of several risk and audit committees in ASX-listed companies.
Dr Brookes is a Fellow of the Australian College of Rural and Remote Medicine, and a Fellow of the Australian Institute of Company Directors.